Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “Patenting natural matters after Mayo and Myriad” at the 6th Annual Intellectual Property Seminar.
我們過去活動
Recommended Insights
Diagnostic Claims in China
2020年1月9日The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
閱讀更多 >
How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?
2020年11月20日The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]
閱讀更多 >
Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?
2020年7月14日This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
閱讀更多 >
Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement
2022年12月2日This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]
閱讀更多 >